In The Zone

JAZZ – Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company’s marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder.

Its product candidate in Phase III clinical trials comprise JZP-6 for the treatment of fibromyalgia. The company’s other product candidates in clinical development comprises JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-7 for the treatment of restless legs syndrome.

Jazz Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Palo Alto, California. Jazz Pharmaceuticals ended the week trading at $4.13 up $0.13 or 8.12% for the week on heavier than average trading volume of 8.8 million.

*** Please have a look at the chart below ***